Glenmark Pharma cuts price of COVID-19 drug by 27 pc to Rs 75/tablet
(This story has not been edited by Business Insider and is auto-generated from a syndicated feed we subscribe to.)
Trending News
Glenmark Pharmaceuticals had launched FabiFlu last month at a price of Rs 103 per tablet.
In a regulatory filing Glenmark announced a price reduction of 27 per cent for FabiFlu. The new maximum retail price (MRP) is Rs 75 per tab, it said.
"The price reduction has been made possible through benefits gained from higher yields and better scale, as both the active pharmaceutical ingredient (API) and formulations are made at Glenmark's facilities in India, the benefits of which are being passed on to patients in the country," the filing said.Further, the company has commenced a post marketing surveillance (PMS) study on FabiFlu to closely monitor the efficacy and safety of the drug in 1,000 patients that are prescribed with the oral antiviral, as part of an open label, multicenter, single arm study, the filing added.
"We expect this post marketing surveillance study to shed more light on the drug's clinical effectiveness and safety in a large cohort of patients prescribed FabiFlu," Malik added.On June 20, Glenmark announced that it received manufacturing and marketing approval from India's drug regulator for FabiFlu, making it the first oral Favipiravir-approved medication in India for the treatment of mild to moderate COVID-19.
Glenmark has also completed the phase 3 clinical trial with Favipiravir (FabiFlu) in mild to moderate COVID-19 patients in India. The trial results will be available shortly, the company said. Glenmark is also conducting another phase 3 clinical trial to evaluate the efficacy of two antivirals drugs Favipiravir and Umifenovir as a combination therapy in moderate hospitalised adult COVID-19 patients in India.(This story has not been edited by Business Insider and is auto-generated from a syndicated feed we subscribe to.)
Copyright © 2021. Times Internet Limited. All rights reserved.For reprint rights. Times Syndication Service.
Next